RxDoctor Payments Data

Steven Kobren

Cardiovascular Disease · Great Neck, NYNPI 1275525446

Payments from drug & device makers

$385in general payments, 2019–2025

Across 24 payments — averaging $16.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$121
  • Novo Nordisk$56
  • Amgen$53
  • Novartis$44
  • Neurocrine Biosciences, Inc.$29
  • E.r. Squibb & Sons, L.L.C.$26
  • plus $55 from 4 others

What the payments were for

  • Food & beverage$385100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$385 in reported general payments places this provider in the 20th percentile of 2,302 cardiovascular disease providers in New York.

See all cardiovascular disease providers in New York

Medicare billing

Part B allowed, 2024
$800,681
Medicare patients
1,099
Services billed
9,506

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban273$288,394
XareltoRivaroxaban198$248,783
EntrestoSacubitril/Valsartan78$86,610
JardianceEmpagliflozin19$16,590
Metoprolol Succinate946$11,722
Atorvastatin Calcium1,110$11,241
Rosuvastatin Calcium904$9,451
Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide649$8,954
Repatha SureclickEvolocumab12$7,849
Losartan Potassium681$7,200
Nebivolol Hcl57$5,205
Amlodipine Besylate688$3,983
Potassium Chloride194$2,691
Simvastatin346$2,687
Alprazolam347$2,224

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$121$248,783198 claims
NovartisEntresto$44$86,61078 claims
AbbVieSynthroid$14$2,22046 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 2,302 cardiovascular disease providers in New York.

Other cardiovascular disease in Great Neck

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →